SG Americas Securities
BTAI icon

SG Americas Securities’s BioXcel Therapeutics BTAI Stock Holding History

SG Americas Securities’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,717
Closed -$574K – 3205
2022
Q2 		$574K Buy
+2,717
New +$571K 0.01% 1847
2021
Q4 		– Sell
-426
Closed -$207K – 3404
2021
Q3 		$207K Buy
+426
New +$187K ﹤0.01% 3213
2021
Q2 		– Sell
-153
Closed -$106K – 2877
2021
Q1 		$106K Buy
+153
New +$123K ﹤0.01% 3051
2020
Q4 		– Sell
-995
Closed -$690K – 3340
2020
Q3 		$690K Buy
+995
New +$747K ﹤0.01% 1422

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG Americas Securities's BTAI Position: Q3 2022 in Review

SG Americas Securities sold out of BioXcel Therapeutics (BTAI) in Q3 2022, closing a stake of 2,717 shares — an estimated $574K sold.

SG Americas Securities first reported a position in BTAI in Q3 2020 and held it in 4 quarters. The position peaked at $690K in Q3 2020. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2022.

  • SG Americas Securities reported no remaining BioXcel Therapeutics position as of Q3 2022 after selling out during the quarter.
  • SG Americas Securities sold 2,717 BioXcel Therapeutics shares in Q3 2022, an estimated $574K.
  • SG Americas Securities first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 4 quarters.
  • SG Americas Securities's BioXcel Therapeutics position peaked at $690K in Q3 2020.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2022.

Based on SG Americas Securities's 13F filing for Q3 2022, filed 31 Oct 2022.